Ontology highlight
ABSTRACT:
SUBMITTER: Aragon-Ching JB
PROVIDER: S-EPMC3720116 | biostudies-other | 2012 Nov
REPOSITORIES: biostudies-other
Asian journal of andrology 20121008 6
Enzalutamide marks the latest addition to the drugs currently approved by the US Food and Drug Administration for metastatic, castration-resistant prostate cancer (mCRPC). AFFIRMwas a phase III international randomized trial that evaluated the clinical utility of enzalutamide versus placebo in men with mCRPC who have failed prior docetaxel-containing chemotherapy. Enzalutamide showed a remarkable 37% decreased risk of death with a median overall survival of 18.4 months versus 13.6 months for tho ...[more]